Lifeloc Tech reports 2022 net loss of $456K despite 20% revenue growth to $8.482M

Lifeloc Technologies, Inc

Revenue $8.482M (+20% YoY); net loss $456K (($0.19)/share) vs net profit $676K ($0.27/share) in 2021.
One-time gain of $108K from employee retention tax credit in 2022; 2021 had $936K PPP loan forgiveness.
L-series devices (LX9/LT7) sales grew 360% vs 2021; expected to continue growth.
SpinDx THC saliva detection testing validates against LCMS at ~10 ng/mL; commercial launch targeted for 2024.
Supply chain disruptions and higher R&D spending drove loss despite revenue recovery to pre-pandemic levels.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.